Last reviewed · How we verify
Lucentis intravitreal injection
Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce vascular permeability in the eye.
Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce vascular permeability in the eye. Used for Neovascular (wet) age-related macular degeneration, Macular edema following retinal vein occlusion, Diabetic macular edema.
At a glance
| Generic name | Lucentis intravitreal injection |
|---|---|
| Sponsor | Medical University of Vienna |
| Drug class | VEGF-A inhibitor (monoclonal antibody fragment) |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Ranibizumab is a recombinant humanized monoclonal antibody fragment that binds and neutralizes all active forms of VEGF-A, a key driver of pathological neovascularization and vascular leakage in retinal diseases. By blocking VEGF-A signaling, it prevents endothelial cell proliferation and reduces fluid accumulation in the retina, thereby slowing or halting vision loss in conditions characterized by abnormal retinal vasculature.
Approved indications
- Neovascular (wet) age-related macular degeneration
- Macular edema following retinal vein occlusion
- Diabetic macular edema
- Diabetic retinopathy
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
- Endophthalmitis
- Retinal detachment
Key clinical trials
- Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (PHASE3)
- Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema (PHASE3)
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) (PHASE4)
- A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME (PHASE3)
- A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD (PHASE3)
- A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PHASE3)
- Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lucentis intravitreal injection CI brief — competitive landscape report
- Lucentis intravitreal injection updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI